Innoviva Appoints New Directors, Discloses Officer Compensation

Ticker: INVA · Form: 8-K · Filed: Apr 30, 2024 · CIK: 1080014

Innoviva, INC. 8-K Filing Summary
FieldDetail
CompanyInnoviva, INC. (INVA)
Form Type8-K
Filed DateApr 30, 2024
Risk Levellow
Pages4
Reading Time5 min
Key Dollar Amounts$0.01, $120,000, $125,000, $18,750, $50,000
Sentimentneutral

Sentiment: neutral

Topics: board-appointment, officer-compensation

Related Tickers: INVA

TL;DR

Innoviva adds two directors to the board, expect more details on exec pay soon.

AI Summary

Innoviva, Inc. announced on April 29, 2024, the appointment of Dr. Steven M. Altschuler and Ms. Jennifer L. Fox to its Board of Directors, effective immediately. The company also disclosed compensatory arrangements for certain officers, though specific details of these arrangements were not provided in this filing.

Why It Matters

Changes in board composition can signal shifts in company strategy or governance, while details on officer compensation are crucial for understanding executive incentives and potential dilution.

Risk Assessment

Risk Level: low — This filing is primarily an informational update regarding board appointments and general disclosure of compensatory arrangements, with no immediate financial implications.

Key Players & Entities

FAQ

Who were the individuals appointed to Innoviva's Board of Directors?

Dr. Steven M. Altschuler and Ms. Jennifer L. Fox were appointed to the Board of Directors.

When were the new directors' appointments effective?

The appointments were effective as of April 29, 2024.

What other information is disclosed in this 8-K filing?

The filing also discloses compensatory arrangements of certain officers.

What is Innoviva, Inc.'s state of incorporation?

Innoviva, Inc. is incorporated in Delaware.

What is Innoviva's business address?

Innoviva's business address is 1350 Old Bayshore Highway, Suite 400, Burlingame, California 94010.

Filing Stats: 1,159 words · 5 min read · ~4 pages · Grade level 11.5 · Accepted 2024-04-29 18:14:52

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit Number Description of Exhibits 104 Cover Page Interactive Data File (embedded within the inline XBRL) - 3 - SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INNOVIVA, INC. Date: April 29, 2024 By: /s/ Pavel Raifeld Pavel Raifeld Chief Executive Officer - 4 -

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing